Literature DB >> 36028658

Should LHRH therapy be continued in patients receiving abiraterone acetate?

Loic Ah-Thiane1, Stéphane Supiot2,3.   

Abstract

Entities:  

Year:  2022        PMID： 36028658     DOI： 10.1038/s41391-022-00584-9

Source DB:  PubMed          Journal:  Prostate Cancer Prostatic Dis        ISSN： 1365-7852            Impact factor:   5.455


× No keyword cloud information.
  4 in total

1.  Expression and cellular localization of follicle-stimulating hormone receptor in normal human prostate, benign prostatic hyperplasia and prostate cancer.

Authors:  Stefania Mariani; Luisa Salvatori; Sabrina Basciani; Mario Arizzi; Giorgio Franco; Elisa Petrangeli; Giovanni Spera; Lucio Gnessi
Journal:  J Urol       Date:  2006-06       Impact factor: 7.450

2.  Expression of follicle-stimulating hormone receptor in tumor blood vessels.

Authors:  Aurelian Radu; Christophe Pichon; Philippe Camparo; Martine Antoine; Yves Allory; Anne Couvelard; Gaëlle Fromont; Mai Thu Vu Hai; Nicolae Ghinea
Journal:  N Engl J Med       Date:  2010-10-21       Impact factor: 91.245

3.  Combined abiraterone acetate plus prednisone, salvage prostate bed radiotherapy and LH-RH agonists (CARLHA-GEP12) in biochemically-relapsing prostate cancer patients following prostatectomy: A phase I study of the GETUG/GEP.

Authors:  Stéphane Supiot; Loic Campion; Pascal Pommier; Mélanie Dore; Clément Palpacuer; Séverine Racadot; Emmanuel Rio; Gérard A Milano; Céline Mahier-Ait Oukhatar; Christian Carrie
Journal:  Oncotarget       Date:  2018-04-24
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.